                         SEQUENCE LISTING

<110>  Ramot at Tel-Aviv University Ltd.
       Universita' degli Studi di Padova
       Satchi-Fainaro, Ronit
       Pasut, Gianfranco
 
<120>  TARGETED POLYMERIC CONJUGATES AND USES THEREOF

<130>  53616

<150>  US 61/484,991
<151>  2011-05-11

<160>  19    

<170>  PatentIn version 3.5

<210>  1
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary pH-sensitive linking moiety

<400>  1

Gly Phe Gly 
1           


<210>  2
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin K cleavable site


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Norleucine

<400>  2

Gly Gly Pro Xaa 
1               


<210>  3
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin D cleavable site

<400>  3

Gly Thr Gln Phe Phe 
1               5   


<210>  4
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin D cleavable site

<400>  4

Gly Ser Thr Phe Phe 
1               5   


<210>  5
<211>  2
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin H cleavable site

<400>  5

Leu Gly 
1       


<210>  6
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin L cleavable site

<400>  6

Ala Phe Arg Ser Ala Ala Gln 
1               5           


<210>  7
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a legumain cleavable site

<400>  7

Ala Ala Asn 
1           


<210>  8
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having an MMP-2 and an MMP-9 cleavable 
       site

<400>  8

His Pro Val Gly Leu Leu Ala Arg 
1               5               


<210>  9
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having an MMP-2 and an MMP-9 cleavable 
       site

<400>  9

Pro Val Ser Leu Ser Tyr 
1               5       


<210>  10
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having an MMP-2 and an MMP-9 cleavable 
       site

<400>  10

Gly Pro Val Gly Leu Ile Gly Lys 
1               5               


<210>  11
<211>  2
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Citrulline

<400>  11

Xaa Val 
1       


<210>  12
<211>  2
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  12

Arg Arg 
1       


<210>  13
<211>  2
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  13

Phe Lys 
1       


<210>  14
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  14

Gly Phe Leu Gly 
1               


<210>  15
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  15

Gly Phe Ala Leu 
1               


<210>  16
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  16

Ala Leu Ala Leu 
1               


<210>  17
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  17

Gly Leu Gly 
1           


<210>  18
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  18

Gly Phe Gly 
1           


<210>  19
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  An example of a linker having a Cathepsin B cleavable site

<400>  19

Gly Phe Leu Gly Phe Lys 
1               5       


